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Abstract
The endothelins (ET-1, 2 and 3) constitute a family of 21 amino acid
peptides with potent biological activities. ET-1 is one of the most
potent endogenous vasoconstrictors so far identified and its increased
concentration in plasma appears to be closely related to the pathogen-
esis of arterial hypertension as well as to obstructive sleep apnea
(OSA). OSA patients exhibit repetitive episodes of apnea and hypopnea
that result in hypoxia and consecutive arousals. These patients are
chronically sleep deprived, which may aggravate the hypertensive
features, since literature data show that sleep deprivation results in
hypertension both in humans and in animals. Based on the reported
relationship between ET-1, hypertension and sleep deprivation conse-
quences, the purpose of the present study was to determine plasma ET
concentrations in paradoxical sleep-deprived animals. Male Wistar
rats, 3 to 4 months old (N = 10 per group), were deprived of sleep for
24 and 96 h by the platform technique and plasma ET-1/2 was
measured by radioimmunoassay. Analysis of plasma revealed that 96
h of sleep deprivation induced a significant increase in ET-1/2 release
(6.58 fmol/ml) compared to control (5.07 fmol/ml). These data show
that sleep deprivation altered plasma ET-1/2 concentrations, suggest-
ing that such an increase may participate in the genesis of arterial
hypertension and cardiorespiratory changes observed after sleep dep-
rivation.
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Endothelins (ET-1, 2 and 3) constitute a
family of 21 amino acid peptides with potent
biological activities. The three isomers pres-
ent slightly different N-terminal amino acid
sequences, yet similar biological activities.
ET-1 is the only family member produced by
endothelial cells (1), and is also produced by
many types of cells, including neurons and
astrocytes in the central nervous system, hepa-
tocytes, and Sertoli cells, among others. ET-
2 and ET-3 are mainly produced within the
kidney and intestine (2). ET-1 is released
under the influence of chemical or physical
stimuli such as hypoxia (3). ET-1 production
is regulated in vitro and in vivo by a variety of
hormones, other vasoactive substances, and
conditions of vascular stress (2). ET-1 is a
powerful mitogenic substance, being the most
potent endogenous vasoconstrictor identi-
fied thus far, and seems to be intimately
involved in the pathogenesis of heart failure,
kidney disease and hypertension (for a re-
view, see 4).
One of the most common sleep disorders
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is obstructive sleep apnea (OSA), which is
characterized by repetitive episodes of up-
per airway collapse during sleep, resulting in
airflow interruption despite persisting respi-
ratory efforts. Several epidemiological and
animal studies have identified OSA as an
important risk factor for systemic hyperten-
sion, but a direct etiologic link between the
two disorders has yet to be definitively es-
tablished (5,6). Some studies have provided
suggestive evidence that, besides involve-
ment of the neural circulatory control
mechanisms, other factors, such as the in-
duction of ET-1 release by episodes of OSA,
may contribute to the risk for the patients (7).
OSA patients exhibit repetitive nocturnal
apneas and hypopneas that result in hypoxia
and consecutive arousals. These patients are
chronically sleep deprived, because of fre-
quent awakenings at the termination of ap-
neic episodes.
Sleep deprivation may aggravate hyper-
tensive features, inasmuch as it is known to
result in hypertension in both humans and
animals (8,9). Sleep deprivation characteris-
tically occurs in a number of sleep disorders
in humans, including insomnia, OSA and
fibromyalgia. This is the primary justifica-
tion for the establishment of controlled ex-
perimental models of sleep deprivation. Para-
doxical sleep deprivation studies using sev-
eral species have produced mixed results,
ranging from minor effects to severe changes
and death (for a review, see 10). The cause of
death is still unclear.
Assuming that there are cardiorespira-
tory changes observed during the period af-
ter paradoxical sleep deprivation (11) and
that ET-1 participates in the genesis of hy-
pertension and heart disease, the present
study was designed to evaluate whether para-
doxical sleep deprivation impairs ET-1 se-
cretion in sleep-deprived animals.
Male Wistar rats weighing ~300 g were
subjected to sleep deprivation using the modi-
fied multiple platform technique (12). The
animals were placed inside a filled water
tank (127 x 44 x 44 cm) containing 15 nar-
row platforms (6.5 cm in diameter), sub-
merged in water until 1 cm below the sur-
face. In this procedure, the animal is aroused
from sleep when the characteristic loss of
muscle tone that accompanies paradoxical
sleep causes it to fall off the platform.
One day before the beginning of the study,
the animals were adapted to the water tank
for a period of 1 h. The animals were divided
into three groups (N = 10/group). One group
was deprived of sleep for 24 h (24-h sleep
deprivation) and the other, for 96 h (96-h
sleep deprivation). Control animals (N = 10)
were maintained in their home cage in the
same room where deprivation took place.
All groups had free access to food and water
throughout the study.
Immediately after the end of the sleep
deprivation, the animals were ether-anesthe-
tized and submitted to blood sampling by
cardiac puncture. Blood was collected into
vials containing sodium citrate and centri-
fuged at 2300 rpm for 10 min. Plasma was
extracted, stored in plastic tubes and frozen
at -70”C until determination of ET-1/2 lev-
els. ET was determined using an ET-1/2
I125 radioimmunoassay kit (Amersham Inter-
national plc, Little Chalfont, Buckingham-
shire, UK). The lower limit of detection for
ET-1/2 was 0.5 fmol/ml and the inter- and
intra-assay coefficients of variation were 10.4
and 4.1%, respectively. Cross-reactivities of
the assay with ET-1, ET-2, ET-3 and big ET
were 100, 204, 0.0024 and 37.9% (human;
1-38), respectively.
ET-1/2 data were analyzed by one-way
ANOVA, followed by the Duncan multiple
range test, with the level of significance set
at P£0.05.
ANOVA revealed a difference among
groups [F(2,27) = 3.31; P£0.05]. Post hoc com-
parison showed that the 96-h sleep depriva-
tion group exhibited a higher response than
the control (P<0.03) and 24-h sleep depriva-
tion (P<0.04) groups. ET-1/2 levels are shown
in Figure 1. The present results show that 96
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h of sleep deprivation by the modified mul-
tiple platform technique resulted in an in-
crease of plasma ET-1/2 levels. Twenty-four
hours of paradoxical sleep deprivation did
not alter the plasma ET-1/2 levels. These
time points were chosen based on a pilot
study in which we observed activation of
endothelial cells only after 24 and 96 h of
paradoxical sleep deprivation.
Numerous studies suggest that increased
ET production or release may contribute to
the pathogenesis of hypertension (4). The
possible involvement of ET in the develop-
ment or maintenance of arterial hyperten-
sion is based on the assumption that these
peptides possess potent vasoconstricting and
long-lasting pressor effects and may play an
important role as circulating and/or local
hormones, affecting vascular tonus and/or
local blood flow.
According to our data, ET-1/2 may con-
tribute to the hypertension observed after
paradoxical sleep deprivation (8,9). The ex-
act mechanism is unknown, but there are
some likely explanations for the alteration in
the pattern of blood pressure after sleep dep-
rivation. First, Mion Jr. and Krieger (8) have
reported that paradoxical sleep deprivation
may impair baroreceptor control function. It
seems unlikely that a peripheral dysfunction
could explain this impairment. Since angio-
tensin II, acting on the central nervous sys-
tem, produces impairment in baroreflex con-
trol (13), and overactivity of the renin-angio-
tensin system could partly account for the
alteration in baroreceptor function. It was
observed that rapid eye movement sleep dep-
rivation of longer duration is associated with
increased hyperresponsiveness to centrally
administered angiotensin II (14). Second,
other studies suggest that lack of sleep may
increase circulating norepinephrine, which
mediates peripheral vasoconstriction via a-
adrenergic receptors, leading to increased
blood pressure and heart rate (9,15). ET-1
potentiates the vasoconstriction caused by
norepinephrine (16) and catecholamines, in
turn, potentiate the action of ET. Synergistic
effects of ET-1 with norepinephrine and with
the renin-angiotensin system raise the possi-
bility of the existence of a common pathway
in the hypertension-producing mechanism
after sleep deprivation. However, Kato et al.
(17) have noted that a shorter period of sleep
deprivation in humans results in increased
blood pressure and no change in heart rate.
These effects are not mediated by sympa-
thetic drive. These authors assume that pro-
duction of ET may be enhanced.
As reviewed by Battistini et al. (4), ET-1
production or release in endothelial and other
cells is regulated by several vasoactive sub-
stances, a variety of hormones, growth fac-
tors and cytokines, among other factors.
According to Kanse et al. (18), glucocorti-
coids have been shown to regulate ET secre-
tion. Recently, Suchecki and Tufik (12)
showed that both ACTH and corticosterone
levels are increased by the multiple platform
technique used to induce paradoxical sleep
deprivation. Several lines of evidence sup-
port the notion that sleep deprivation is a
stressful method. Moreover, it is still unclear
whether sleep deprivation by itself is a stress-
ful stimulus. Thus, it is tempting to speculate
that elevation of ET levels observed after
paradoxical sleep deprivation may be medi-
ated by activation of the hypothalamus-pitu-
itary-adrenal axis.
Recently, Kähler et al. (19) demonstrated
that oxidative stress increases the activity of
the ET-1 promoter, preproendothelin-1
mRNA and big ET-1 protein synthesis. In-
terestingly, exposure of animals to the single
platform technique results in increased oxi-
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Figure 1. Plasma levels of endo-
thelin-1/2 (fmol/ml) after para-
doxical sleep deprivation. Values
are reported as mean ± SEM.
Control (N = 10); PSD24 - para-
doxical sleep deprivation for 24
h (N = 10); PSD96 - paradoxical
sleep deprivation for 96 h (N =
10). *P£0.05 compared to con-
trol and PSD24 groups (ANOVA).
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dative stress, reflected by reduced levels of
the antioxidant glutathione in hypothalamus
and thalamus (20). According to these data,
a paradoxical sleep deprivation-induced oxi-
dative process may contribute to the aug-
mented plasma ET-1 levels.
Such findings indicate that paradoxical
sleep deprivation disrupts vital biological
processes necessary for physical health; how-
ever, how brain and body functions become
compromised is not yet fully understood.
The most important factor is that paradoxi-
cal sleep loss (to different extents) is experi-
enced by almost everybody and, thus, prob-
ably can be considered a near natural phe-
nomenon in terms of applicability of the
knowledge for the ultimate goal, human wel-
fare. Sleep loss can induce a variety of seri-
ous problems, which have been neglected as
subjects of study.
Our results showed that paradoxical sleep
deprivation increased plasma ET-1/2 levels,
suggesting that such an increase may partici-
pate in the genesis of arterial hypertension
observed after paradoxical sleep depriva-
tion. Vasoconstrictor and mitogenic effects
of ET-1 may contribute to the development
of chronic conditions such as hypertension
and cardiovascular disease in situations of
sleep deprivation. This result adds further
evidence demonstrating sleep deprivation-
induced physiological alterations. Future
studies should provide a clearer understand-
ing of the mechanisms involved in the para-
doxical sleep deprivation-induced increase
of ET secretion.
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